Remdesivir

Remdesivir (GS-5734) is a nucleoside analogue with effective antiviral activity. Remdesivir can inhibit the synthesis of viral DNA or RNA. Remdesivir can be used for the research of infection, such as SARS-CoV and MHV infection^[1][2][3]. IC50 & Target:EC₅₀: 30 nM (murine hepatitis virus, delayed brain tumor cell), 74 nM (SARS-CoV, HAE cell), 74 nM (MERS-CoV, HAE cell)^[1]
EC₅₀: 3.3 μM (SARS-CoV-2), 4.7 μM (SARS-CoV-2 alpha), 32 μM (SARS-CoV-2 beta), 3.7 μM (SARS-CoV-2 gamma) and 9.2 μM (SARS-CoV-2 delta)^[3] In Vitro:Remdesivir inhibits MHV replication with an IC₅₀ of 1.1 μM in infected delayed brain tumor (DBT) cells with MHV^[1].
Remdesivir (2 μM, 2 h preinfection and 2 h postinfection) shows maximal inhibition in infected cells with MHV^[1].
Remdesivir (1-10 μM, 24-72 h) decreases SARS-CoV and MERS-CoV viral titer in HAE cells^[1].
Remdesivir inhibits 2019-nCoV with an EC₅₀ of 0.77 μM and CC₅₀ >100 μM^[2].
Remdesivir shows antiviral activity with EC₅₀ values of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively^[3].
In Vivo:Remdesivir (0.01-100 μM) reduces lung viral titers in mice models of WT and F480L + V557L SARS-CoV^[1].
Remdesivir (10 mg/kg, i.v.) shows 100% protection against Ebola virus infection in nonhuman primate (NHP) models^[2].